SCHEMBL4768655

SCHEMBL4768655

CSc1ccc(C2=NC(=O)c3ccccc3C2)cc1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGS2 P35354 5/20 0.42
PTGS1 P23219 3/20 0.42
GCGR P47871 1/20 0.39
MAOA P21397 1/20 0.37
BCHE P06276 1/20 0.35
CES1 P23141 1/20 0.35
ALDH1A1 P00352 4/20 0.34
GAA P10253 2/20 0.34
MAPT P10636 2/20 0.34
KDM4E B2RXH2 1/20 0.34
GLA P06280 1/20 0.34
HPGD P15428 1/20 0.34
RAB9A P51151 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
DHODH Q02127 1/20 0.34
ACHE P22303 1/20 0.33
NISCH Q9Y2I1 1/20 0.33
TDP2 O95551 1/20 0.33
CASP3 P42574 1/20 0.33
CASP7 P55210 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4774575 0.80 MAOA (0.40) MAOABCHECES1ALDH1A1GAA
SCHEMBL13945302 0.80 MIF (0.44) MAOABCHECES1ALDH1A1GAA
SCHEMBL4769027 0.79 NPC1 (0.46) ALDH1A1GAAMAPTKDM4EHPGD
SCHEMBL4763729 0.77 PDCD1 (0.43) MAOABCHECES1ALDH1A1MAPT
SCHEMBL4766650 0.75 HSD11B1 (0.42) DHODHNISCH
SCHEMBL7764516 0.74 MAOA (0.44) MAOABCHECES1ALDH1A1GAA
SCHEMBL4769387 0.73 NOTUM (0.38) MAOAKDM4ENISCHFFAR1FFAR4
SCHEMBL4766311 0.73 MEN1 (0.48) ALDH1A1MAPTKDM4EHPGDRAB9A
SCHEMBL4771354 0.72 ABL1 (0.44) MAOAALDH1A1GAAMAPTKDM4E
SCHEMBL18918388 0.72 BRD4 (0.47) MAOAACHE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1020445-B1 FUSED PYRIDINE DERIVATIVES EISAI R&D MAN CO LTD (JP) 2008-08-13 EP disclosed
US-6875761-B2 Certain 1,3-disubstituted isoquinoline derivatives EISAI CO., LTD. (JP) 2005-04-05 US disclosed
US-20040204421-A1 Certain 1,3-disubstituted isoquinoline derivatives EISAI CO., LTD. 2004-10-14 US disclosed
US-6790844-B2 MUSCLE RELAXANTS; ANTISEROTONINE AGENT EISAI CO., LTD (JP) 2004-09-14 US disclosed
US-20020013460-A1 Condensed pyridine compound EISAI CO., LTD 2002-01-31 US disclosed
US-6340759-B1 ANTISPASMODIC AGENTS EISAI CO., LTD. (JP) 2002-01-22 US disclosed
EP-1020445-A1 FUSED PYRIDINE DERIVATIVES Eisai Co., Ltd. (JP) 2000-07-19 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020013460-A1 Condensed pyridine compound MUSK, HTR1A, PAX3 PTGS2 392/4885PTGS1 175/4885GCGR 3796/4885
US-20040204421-A1 Certain 1,3-disubstituted isoquinoline derivatives MUSK, HTR1A, RYR1 PTGS2 233/4885PTGS1 88/4885GCGR 2904/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.